×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
INCY – incyte corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
INCY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/8
10:18 pm
incy
Incyte (INCY) Q4 Earnings: What To Expect [Yahoo! Finance]
Low
Report
Incyte (INCY) Q4 Earnings: What To Expect [Yahoo! Finance]
2/6
07:07 am
incy
Incyte (NASDAQ:INCY) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Medium
Report
Incyte (NASDAQ:INCY) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
2/5
04:21 pm
incy
TD Cowen Keeps Buy Rating on Incyte (INCY), Cites Roadmap to Triple Non-Jakafi Revenue by 2029 [Yahoo! Finance]
Medium
Report
TD Cowen Keeps Buy Rating on Incyte (INCY), Cites Roadmap to Triple Non-Jakafi Revenue by 2029 [Yahoo! Finance]
2/5
07:00 am
incy
Incyte (NASDAQ:INCY) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $135.00 price target on the stock.
Low
Report
Incyte (NASDAQ:INCY) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $135.00 price target on the stock.
2/4
02:58 pm
incy
Analysts Differ in Opinion on Jakafi Drug Maker Incyte (INCY) [Yahoo! Finance]
Low
Report
Analysts Differ in Opinion on Jakafi Drug Maker Incyte (INCY) [Yahoo! Finance]
2/4
06:09 am
incy
Incyte (NASDAQ:INCY) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Low
Report
Incyte (NASDAQ:INCY) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
2/4
12:33 am
incy
How Investors Are Reacting To Incyte (INCY) EMA Boost For Zynyz In First-Line Anal Cancer [Yahoo! Finance]
Low
Report
How Investors Are Reacting To Incyte (INCY) EMA Boost For Zynyz In First-Line Anal Cancer [Yahoo! Finance]
2/3
11:42 am
incy
Prelude climbs as FDA clears study for Incyte-partnered cancer candidate [Seeking Alpha]
Low
Report
Prelude climbs as FDA clears study for Incyte-partnered cancer candidate [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/4
04:07 pm
incy
Form 4 INCYTE CORP For: Feb 02 Filed by: Heeson Lee
Low
Report
Form 4 INCYTE CORP For: Feb 02 Filed by: Heeson Lee
2/4
04:07 pm
incy
Form 4 INCYTE CORP For: Feb 02 Filed by: Morrissey Michael James
Low
Report
Form 4 INCYTE CORP For: Feb 02 Filed by: Morrissey Michael James
1/21
04:07 pm
incy
Form 4 INCYTE CORP For: Jan 16 Filed by: Heeson Lee
Low
Report
Form 4 INCYTE CORP For: Jan 16 Filed by: Heeson Lee
1/21
04:07 pm
incy
Form 4 INCYTE CORP For: Jan 16 Filed by: CAGNONI PABLO J
Low
Report
Form 4 INCYTE CORP For: Jan 16 Filed by: CAGNONI PABLO J
1/21
04:06 pm
incy
Form 4 INCYTE CORP For: Jan 16 Filed by: Trotta Matteo
Low
Report
Form 4 INCYTE CORP For: Jan 16 Filed by: Trotta Matteo
1/21
04:06 pm
incy
Form 4 INCYTE CORP For: Jan 16 Filed by: Stein Steven H
Low
Report
Form 4 INCYTE CORP For: Jan 16 Filed by: Stein Steven H
1/21
04:06 pm
incy
Form 4 INCYTE CORP For: Jan 16 Filed by: Issa Mohamed Khairie
Low
Report
Form 4 INCYTE CORP For: Jan 16 Filed by: Issa Mohamed Khairie
1/21
04:05 pm
incy
Form 4 INCYTE CORP For: Jan 16 Filed by: Tray Thomas
Low
Report
Form 4 INCYTE CORP For: Jan 16 Filed by: Tray Thomas
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/5
Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream at the Revolutionizing Atopic Dermatitis Virtual Symposium
7.1%
7/30 Incyte Reports 2019 Second Quarter Financial Results and Provides Updates on Key Clinical Programs 6.4%
3/13 Incyte Co. (NASDAQ: INCY) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. They now have a $83.00 price target on the stock. 6.4%
3/26 Incyte Names New Member to Its Board of Directors 5.9%
1/13 Incyte Co. (NASDAQ: INCY) had its "buy" rating re-affirmed by analysts at Cowen Inc. 5.7%
11/25 Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 61st Annual ASH Meeting 5.3%
4/15 Form 4 INCYTE CORP For: Apr 13 Filed by: Pasquale Maria E 5.2%
2/18 Form 4 INCYTE CORP For: Feb 13 Filed by: Pasquale Maria E 4.0%
9/19 Form 4 INCYTE CORP For: Sep 18 Filed by: SWAIN PAULA J 4.0%
3/24 Blair likes Incyte in premarket analyst action [Seeking Alpha] 3.5%
7/30 Incyte Reports 2019 Second Quarter Financial Results and Provides Updates on Key Clinical Programs 6.4%
3/13 Incyte Co. (NASDAQ: INCY) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. They now have a $83.00 price target on the stock. 6.4%
3/26 Incyte Names New Member to Its Board of Directors 5.9%
1/13 Incyte Co. (NASDAQ: INCY) had its "buy" rating re-affirmed by analysts at Cowen Inc. 5.7%
11/25 Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 61st Annual ASH Meeting 5.3%
4/15 Form 4 INCYTE CORP For: Apr 13 Filed by: Pasquale Maria E 5.2%
2/18 Form 4 INCYTE CORP For: Feb 13 Filed by: Pasquale Maria E 4.0%
9/19 Form 4 INCYTE CORP For: Sep 18 Filed by: SWAIN PAULA J 4.0%
3/24 Blair likes Incyte in premarket analyst action [Seeking Alpha] 3.5%
TOP News Decliners
1/2
Incyte Announces Results of Phase 3 Study of Itacitinib in Patients with Treatment-Naïve Acute Graft-Versus-Host Disease
-9.4%
5/10 Form 4 INCYTE CORP For: May 09 Filed by: Iyengar Vijay K -6.1%
3/26 Form 8-K INCYTE CORP For: Mar 25 -5.6%
6/7 Form SC 13D/A INCYTE CORP Filed by: BAKER BROS. ADVISORS LP -5.0%
9/23 Incyte to Host Investor Conference Call from ESMO 2019 -4.6%
1/28 Incyte's skin disease drug meets main goal in late-stage study [Reuters] -3.8%
3/10 Incyte Joins Elite List Of Stocks With 95-Plus Composite Rating [Investor's Business Daily] -3.2%
9/27 Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma -3.2%
9/12 Incyte Co. (NASDAQ: INCY) is now covered by analysts at BMO Capital Markets. They set a "market perform" rating on the stock. -3.1%
8/27 BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019 -3.1%
5/10 Form 4 INCYTE CORP For: May 09 Filed by: Iyengar Vijay K -6.1%
3/26 Form 8-K INCYTE CORP For: Mar 25 -5.6%
6/7 Form SC 13D/A INCYTE CORP Filed by: BAKER BROS. ADVISORS LP -5.0%
9/23 Incyte to Host Investor Conference Call from ESMO 2019 -4.6%
1/28 Incyte's skin disease drug meets main goal in late-stage study [Reuters] -3.8%
3/10 Incyte Joins Elite List Of Stocks With 95-Plus Composite Rating [Investor's Business Daily] -3.2%
9/27 Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma -3.2%
9/12 Incyte Co. (NASDAQ: INCY) is now covered by analysts at BMO Capital Markets. They set a "market perform" rating on the stock. -3.1%
8/27 BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019 -3.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: